ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

11:00AM-12:30PM: Abstract Number: 1583

Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Plenary II

11:00AM-12:30PM: Abstract Number: 1580

CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Plenary II

11:00AM-12:30PM: Abstract Number: 1584

Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

Plenary II

11:00AM-12:30PM: Abstract Number: 1581

Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Plenary II

11:00AM-12:30PM: Abstract Number: 1582

Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Plenary II

11:00AM-12:30PM: Abstract Number: 1579

Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

Plenary II

2:00PM-3:30PM: Abstract Number: 1596

A Cell and Transcriptomic Atlas of the Infrapatellar Fat Pad from Patients with Knee Osteoarthritis: Identification of an Obesity-Associated Transcriptomic Signature

Abstracts: Osteoarthritis & Joint Biology – Basic Science

2:00PM-3:30PM: Abstract Number: 1654

A Peer Health Coached Resilience-Based Energy Management Program Was Effective in Improving Fatigue and Other Outcomes in People with Systemic Sclerosis: Results of a Randomized Controlled Trial

Abstracts: Interprofessional Exemplary

2:00PM-3:30PM: Abstract Number: 1645

Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Imaging

2:00PM-3:30PM: Abstract Number: 1647

Association Between Vascular FDG Uptake at Diagnosis and Evolution in Aortic Dimensions in Giant Cell Arteritis: A Prospective Study

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Imaging

2:00PM-3:30PM: Abstract Number: 1609

Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes

2:00PM-3:30PM: Abstract Number: 1607

Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus

Abstracts: Antiphospholipid Syndrome

2:00PM-3:30PM: Abstract Number: 1590

Autoimmune Pathway Blockade by a Potent Orally Bioavailable STING Antagonist

Abstracts: Innate Immunity

2:00PM-3:30PM: Abstract Number: 1651

Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

Abstracts: Interprofessional Exemplary

2:00PM-3:30PM: Abstract Number: 1620

Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab

Abstracts: Health Services Research II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].